[1]
Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, Nishio H, Matsuo M. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of human genetics. 2010 Jun:55(6):379-88. doi: 10.1038/jhg.2010.49. Epub 2010 May 20
[PubMed PMID: 20485447]
Level 3 (low-level) evidence
[2]
. Romitti et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics. 2015;135(3):513-521. Pediatrics. 2015 May:135(5):945. doi: 10.1542/peds.2015-0652. Epub
[PubMed PMID: 25934896]
[3]
D'Amario D, Gowran A, Canonico F, Castiglioni E, Rovina D, Santoro R, Spinelli P, Adorisio R, Amodeo A, Perrucci GL, Borovac JA, Pompilio G, Crea F. Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine. Journal of clinical medicine. 2018 Sep 19:7(9):. doi: 10.3390/jcm7090291. Epub 2018 Sep 19
[PubMed PMID: 30235804]
[4]
Hoffman EP,Fischbeck KH,Brown RH,Johnson M,Medori R,Loike JD,Harris JB,Waterston R,Brooke M,Specht L, Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. The New England journal of medicine. 1988 May 26
[PubMed PMID: 3285207]
[5]
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet. Neurology. 2003 Dec:2(12):731-40
[PubMed PMID: 14636778]
[6]
Li QX, Yang H, Zhang N, Xiao B, Bi FF, Li J. [Clinical and pathological features of 50 children with Duchenne's muscular dystrophy]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2012 Oct:14(10):746-50
[PubMed PMID: 23092565]
[7]
Beggs AH. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation. 1997 May 20:95(10):2344-7
[PubMed PMID: 9170393]
[8]
Battini R,Chieffo D,Bulgheroni S,Piccini G,Pecini C,Lucibello S,Lenzi S,Moriconi F,Pane M,Astrea G,Baranello G,Alfieri P,Vicari S,Riva D,Cioni G,Mercuri E, Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions. Neuromuscular disorders : NMD. 2018 Feb
[PubMed PMID: 29305139]
[9]
Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscular disorders : NMD. 2010 Aug:20(8):479-92. doi: 10.1016/j.nmd.2010.04.008. Epub
[PubMed PMID: 20627570]
[10]
Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N, Ikeda S. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. European neurology. 1999:42(3):145-9
[PubMed PMID: 10529540]
[11]
Cox GF, Kunkel LM. Dystrophies and heart disease. Current opinion in cardiology. 1997 May:12(3):329-43
[PubMed PMID: 9243091]
Level 3 (low-level) evidence
[12]
McMillan HJ,Gregas M,Darras BT,Kang PB, Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics. 2011 Jan
[PubMed PMID: 21149430]
[13]
Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005 Nov 1:112(18):2799-804
[PubMed PMID: 16246949]
[14]
Allen HD, Flanigan KM, Thrush PT, Dvorchik I, Yin H, Canter C, Connolly AM, Parrish M, McDonald CM, Braunlin E, Colan SD, Day J, Darras B, Mendell JR. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. PLoS currents. 2013 Dec 12:5():. pii: ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865. doi: 10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865. Epub 2013 Dec 12
[PubMed PMID: 24459612]
Level 1 (high-level) evidence
[15]
Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C, Quality Standards Subcommittee of the American Academy of Neurology, Practice Committee of the Child Neurology Society. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005 Jan 11:64(1):13-20
[PubMed PMID: 15642897]
Level 2 (mid-level) evidence
[16]
King WM,Ruttencutter R,Nagaraja HN,Matkovic V,Landoll J,Hoyle C,Mendell JR,Kissel JT, Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 May 8
[PubMed PMID: 17485648]
[17]
Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L, American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. American journal of respiratory and critical care medicine. 2004 Aug 15:170(4):456-65
[PubMed PMID: 15302625]
Level 3 (low-level) evidence
[18]
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet. Neurology. 2010 Feb:9(2):177-89. doi: 10.1016/S1474-4422(09)70272-8. Epub 2009 Nov 27
[PubMed PMID: 19945914]
Level 3 (low-level) evidence
[19]
Towbin JA. A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy? Journal of the American College of Cardiology. 2003 Jul 16:42(2):317-8
[PubMed PMID: 12875770]
[20]
Bamaga AK, Riazi S, Amburgey K, Ong S, Halliday W, Diamandis P, Guerguerian AM, Dowling JJ, Yoon G. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study. Neuromuscular disorders : NMD. 2016 Mar:26(3):201-6. doi: 10.1016/j.nmd.2016.02.007. Epub 2016 Feb 23
[PubMed PMID: 26951757]
Level 2 (mid-level) evidence
[21]
Jacobson RD, Feldman EL. Antisense Oligonucleotides for Duchenne Muscular Dystrophy: Why No Neurologist Should Skip This. JAMA neurology. 2016 Mar:73(3):259-60. doi: 10.1001/jamaneurol.2015.4011. Epub
[PubMed PMID: 26746046]
[22]
Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). Journal of child neurology. 2010 Sep:25(9):1158-64. doi: 10.1177/0883073810371129. Epub 2010 Jun 2
[PubMed PMID: 20519671]
[23]
Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988 Jan:2(1):90-5
[PubMed PMID: 3384440]